{"entity":{"id":"eribulin","kind":"drug","name":"Eribulin","aka":[],"tldr":"A sea-sponge-derived chemotherapy that extended survival in heavily pretreated breast cancer and in liposarcoma, where almost nothing else had.","summary":"EMBRACE (Lancet 2011): OS 13.1 vs 10.6 months versus treatment of physician's choice in pretreated metastatic breast cancer. Liposarcoma approval 2016 (OS 15.6 vs 8.4 months versus dacarbazine in the liposarcoma subgroup). Neuropathy and neutropenia; the payload of the ADC MORAb-202 (farletuzumab ecteribulin).","status":"approved","asOf":"2026-09-08","wikipedia":"https://en.wikipedia.org/wiki/Eribulin","links":[{"label":"EMBRACE (Lancet 2011)","url":"https://doi.org/10.1016/S0140-6736(11)60070-6"},{"label":"Label (DailyMed)","url":"https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&query=eribulin"}],"tags":["gap-fill"],"related":[],"cancers":["breast-hr-positive","tnbc","sarcoma","liposarcoma"],"sections":[],"technologies":["cytotoxic-chemotherapy"],"targets":[],"drugs":[],"companies":["eisai"],"institutions":[],"pathways":[],"terms":["payload"],"trials":["nct06435429","nct05824975","nct06081959","nct05458674","nct06202261","nct05814354","nct06942234","nct06343948","nct06449222","nct07173751","nct07007559","nct06957886","nct06279364","nct04639986","keynote-119","ascent","destiny-breast04"],"people":[],"bottlenecks":[],"keyPapers":["paper-cortes-lancet"],"journals":[],"dependsOn":[],"notes":[],"brand":"Halaven","modality":"Synthetic halichondrin B analogue (microtubule dynamics inhibitor)","mechanism":"Binds the plus ends of microtubules, suppressing growth without affecting shortening; also reverses EMT and remodels tumour vasculature.","approvals":[{"region":"US","year":2010,"indication":"Metastatic breast cancer after ≥2 regimens including an anthracycline and a taxane"},{"region":"US","year":2016,"indication":"Unresectable or metastatic liposarcoma after anthracycline"},{"region":"EU","year":2011,"indication":"Metastatic breast cancer; liposarcoma (2016)"}],"mechanismSteps":[],"toxicity":[],"access":[],"regulatoryEvents":[]},"route":"/drugs/eribulin/","neighbours":{"cancer":[{"id":"breast-hr-positive","kind":"cancer","name":"HR-positive / HER2-negative breast cancer","route":"/cancers/breast-hr-positive/"},{"id":"liposarcoma","kind":"cancer","name":"Liposarcoma","route":"/cancers/liposarcoma/"},{"id":"tnbc-metastatic","kind":"cancer","name":"Metastatic triple-negative breast cancer","route":"/cancers/tnbc-metastatic/"},{"id":"retroperitoneal-sarcoma","kind":"cancer","name":"Retroperitoneal sarcoma","route":"/cancers/retroperitoneal-sarcoma/"},{"id":"sarcoma","kind":"cancer","name":"Sarcomas (soft tissue, bone, GIST)","route":"/cancers/sarcoma/"},{"id":"extremity-soft-tissue-sarcoma","kind":"cancer","name":"Soft tissue sarcoma of the extremity (localised and advanced)","route":"/cancers/extremity-soft-tissue-sarcoma/"},{"id":"tnbc","kind":"cancer","name":"Triple-negative breast cancer (TNBC)","route":"/cancers/tnbc/"},{"id":"uterine-sarcoma","kind":"cancer","name":"Uterine sarcoma","route":"/cancers/uterine-sarcoma/"}],"technology":[{"id":"cytotoxic-chemotherapy","kind":"technology","name":"Cytotoxic chemotherapy","route":"/technologies/cytotoxic-chemotherapy/"}],"company":[{"id":"eisai","kind":"company","name":"Eisai","route":"/companies/eisai/"},{"id":"gi-innovation","kind":"company","name":"GI Innovation","route":"/companies/gi-innovation/"}],"term":[{"id":"payload","kind":"term","name":"Payload (ADC)","route":"/terms/payload/"}],"trial":[{"id":"nct07441512","kind":"trial","name":"A Phase II, Single-arm Study to Evaluate the Efficacy and Safety of Inavolisib in Combination With Eribulin in Pretreated Advanced Triple-negative Breast Cancer","route":"/trials/nct07441512/"},{"id":"nct06343948","kind":"trial","name":"A Study Comparing BL-B01D1 With Chemotherapy of Physician's Choice in Patients With Unresectable Locally Advanced, Recurrent, or Metastatic HR+HER2- Breast Cancer(PANKU-Breast01)","route":"/trials/nct06343948/"},{"id":"nct06435429","kind":"trial","name":"A Study Comparing the Efficacy and Safety of Zanidatamab to Trastuzumab, Each in Combination With Physician's Choice Chemotherapy, for the Treatment o","route":"/trials/nct06435429/"},{"id":"nct03424005","kind":"trial","name":"A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Patients With Metastatic or Locally Advanced Breast Cancer","route":"/trials/nct03424005/"},{"id":"nct06957886","kind":"trial","name":"A Study of BL-M07D1 Versus Investigator's Choice of Chemotherapy in Patients With HER2-low Recurrent/Metastatic Breast Cancer","route":"/trials/nct06957886/"},{"id":"nct05570253","kind":"trial","name":"A Study of SDX-7320 in Combination With Eribulin for People With Breast Cancer","route":"/trials/nct05570253/"},{"id":"nct06279364","kind":"trial","name":"A Study of SKB264 Versus Investigator's Choice Chemotherapy in Patients With Unresectable Recurrent or Metastatic Triple-Negative Breast Cancer","route":"/trials/nct06279364/"},{"id":"nct06202261","kind":"trial","name":"A Study of TQB2930 for Injection Monotherapy or Combination Therapy in Patients With Recurrent/Metastatic Breast Cancer","route":"/trials/nct06202261/"},{"id":"nct05824975","kind":"trial","name":"A Study to Evaluate the Safety and Therapeutic Activity of GI-102 As a Single Agent and in Combination with Conventional Anti-cancer Drugs, Pembrolizu","route":"/trials/nct05824975/"},{"id":"ascent","kind":"trial","name":"ASCENT","route":"/trials/ascent/"},{"id":"nct04639986","kind":"trial","name":"Asian Study of Sacituzumab Govitecan (IMMU-132) in HR+/HER2- Metastatic Breast Cancer (MBC)","route":"/trials/nct04639986/"},{"id":"nct07007559","kind":"trial","name":"ASPEN-09-03: A Study of Evorpacept in Combination With Trastuzumab and Chemotherapy in Metastatic HER2-Positive Breast Cancer","route":"/trials/nct07007559/"},{"id":"nct07255612","kind":"trial","name":"Bone Marrow Protection, Safety, Efficacy of Trilaciclib and Eribulin in Locally Advanced or Metastatic TNBC(Triple-negative Breast Cancer)","route":"/trials/nct07255612/"},{"id":"destiny-breast04","kind":"trial","name":"DESTINY-Breast04","route":"/trials/destiny-breast04/"},{"id":"embraca","kind":"trial","name":"EMBRACA","route":"/trials/embraca/"},{"id":"nct05760378","kind":"trial","name":"Famitinib in Combination With Camrelizumab and TPC in The First-line Treatment of Immunomodulatory Locally Advanced or Metastatic TNBC.","route":"/trials/nct05760378/"},{"id":"nct06731153","kind":"trial","name":"JAK1 Inhibitor Ivarmacitinib Reversing Immunotherapy Resistance in TNBC","route":"/trials/nct06731153/"},{"id":"keynote-119","kind":"trial","name":"KEYNOTE-119","route":"/trials/keynote-119/"},{"id":"nct06387628","kind":"trial","name":"LM-108 in Combination With PD-1 Based Treatment for Patients With Recurrent or Metastatic Triple - Negative Breast Cancer","route":"/trials/nct06387628/"},{"id":"olympiad","kind":"trial","name":"OlympiAD","route":"/trials/olympiad/"},{"id":"nct06889688","kind":"trial","name":"Phase III Trial of Camrelizumab+Apatinib+Eribulin vs. Physician's Choice Chemotherapy in Advanced Triple-Negative Breast Cancer","route":"/trials/nct06889688/"},{"id":"nct07173751","kind":"trial","name":"ROSETTA Breast-01: The Effects and Safety of Pumitamig in Patients With Triple-Negative Breast Cancer","route":"/trials/nct07173751/"},{"id":"nct06449222","kind":"trial","name":"Safety and Preliminary Effectiveness of BNT327, an Investigational Therapy for Breast Cancer, When Given in Combination With Chemotherapy","route":"/trials/nct06449222/"},{"id":"nct04986579","kind":"trial","name":"Scalp Cooling in MBC","route":"/trials/nct04986579/"},{"id":"nct05814354","kind":"trial","name":"SHR-A1811 Versus Investigator's Chemotherapy in Recurrent/Metastatic Breast Cancer Clinical Trial","route":"/trials/nct05814354/"},{"id":"nct06202313","kind":"trial","name":"Study of Cadonilimab (AK104) Plus Eribulin vs. Eribulin Monotherapy for Recurrent or Metastatic Triple-negative Breast Cancer","route":"/trials/nct06202313/"},{"id":"nct06942234","kind":"trial","name":"Study of JSKN016 Combination Therapy in Inoperable Locally Advanced or Metastatic HER2-Negative Breast Cancer","route":"/trials/nct06942234/"},{"id":"nct06081959","kind":"trial","name":"Study of SKB264 for Locally Advanced, Recurrent or Metastatic HR+/HER2- Breast Cancer","route":"/trials/nct06081959/"},{"id":"nct03262935","kind":"trial","name":"SYD985 vs. Physician's Choice in Participants With HER2-positive Locally Advanced or Metastatic Breast Cancer","route":"/trials/nct03262935/"},{"id":"nct05458674","kind":"trial","name":"Tucatinib+Trastuzumab+Eribulin in HER2+ MBC","route":"/trials/nct05458674/"}],"paper":[{"id":"paper-cortes-lancet","kind":"paper","name":"Eribulin monotherapy versus treatment of physician's choice in patients with metastatic breast cancer (EMBRACE): a phase 3 open-label randomised study","route":"/key-papers/paper-cortes-lancet/"},{"id":"paper-eribulin-liposarcoma-schoffski-lancet-2016","kind":"paper","name":"Eribulin versus dacarbazine in previously treated advanced liposarcoma or leiomyosarcoma","route":"/key-papers/paper-eribulin-liposarcoma-schoffski-lancet-2016/"}],"target":[{"id":"tubulin","kind":"target","name":"Tubulin (microtubules)","route":"/targets/tubulin/"}],"pathway":[{"id":"mitotic-spindle-checkpoint","kind":"pathway","name":"Mitosis & the spindle assembly checkpoint","route":"/pathways/mitotic-spindle-checkpoint/"}]}}